Cypherpunk Technologies closed at $2.87 on Nov 4, up 10.38%, 30.3% below its 52-week closing high. Volume of 18.4M shares was 1.48× its 20-day average (above normal).
Split-adjusted performance: -12.0% over one month, +154.0% over six months.
Short interest was 14.8M shares at the Oct 15 settlement, up 9.8% from the prior report (19.5% of float, 1.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CYPHCypherpunk Technologies | $2.87 | +10.38% | +154.0% | — | — | — | $309.3M | |
| ARCTArcturus Therapeutics Holdings | $10.87 | +13.94% | +19.1% | −89.5% | −803.8% | — | $309.0M | Compare |
| ENTAEnanta Pharmaceuticals | $10.65 | +2.70% | −30.1% | −21.6% | −135.8% | — | $310.2M | Compare |
| SPRYARS Pharmaceuticals | $3.05 | 0.00% | −67.1% | +114.2% | −185.2% | — | $303.3M | Compare |
| EBSEmergent Biosolutions | $5.90 | −5.60% | −35.2% | −52.4% | −29.7% | — | $302.5M | Compare |
| CGCCanopy Growth | $0.7517 | +6.37% | −34.6% | +7.8% | −18.0% | — | $318.0M | Compare |
| TTRXTurn Therapeutics | $9.80 | +3.05% | +158.2% | — | — | — | $297.6M | Compare |
| BNTCBenitec Biopharma | $9.28 | +10.48% | −26.2% | — | — | — | $323.8M | Compare |
| PRLDPrelude Therapeutics Incorporated | $4.08 | +7.94% | −15.7% | — | −244.1% | — | $325.6M | Compare |
No recent articles focused on Cypherpunk Technologies. 2 articles mention it in passing.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
